(Q38518518)

3 September 2017

1 reference

title

Intratumoral immunotherapy for melanoma (English)

1 reference

3 September 2017

1 reference

Manisha Singh

1

1 reference

3 September 2017

Willem W Overwijk

series ordinal

2

1 reference

3 September 2017

publication date

7 June 2015

1 reference

Cancer Immunology, Immunotherapy

3 September 2017

published in

1 reference

3 September 2017

volume

64

1 reference

3 September 2017

issue

7

1 reference

3 September 2017

page(s)

911-921

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-015-1727-z

3 September 2017

exact match

0 references

cites work

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Turning tumors into vaccines: co-opting the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Role of bacillus Calmette-Guérin in the treatment of advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Bacillus Calmette-Guérin-activated murine macrophages kill syngeneic melanoma cells under strict anaerobic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intratumoral injection of attenuated Salmonella vaccine can induce tumor microenvironmental shift from immune suppressive to immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Viruses in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Newcastle disease virus (NDV): brief history of its oncolytic strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

21 January 2018

Oncolytic virotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Tumor infection by oncolytic reovirus primes adaptive antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Measles virus causes immunogenic cell death in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Potentiating cancer immunotherapy using an oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intralesional immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Engineering HSV-1 vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-α-mediated antitumor reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intratumoral immunization: a new paradigm for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Local immunomodulation for cancer therapy: Providing treatment where needed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

New perspectives on type I IFNs in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

STING-ing the antiviral pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

STING and the innate immune response to nucleic acids in the cytosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

The STING pathway and the T cell-inflamed tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

The role of topical immune response modifiers in skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Treatment of cutaneous tumors with topical 5% imiquimod cream.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts--results of an open-label, multicentre Phase IIIB trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Plasmid IL-12 electroporation in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

IFN{gamma} markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1727-Z

10.1007/S00262-015-1727-Z

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1010648370

0 references

1 reference